Advertisement
Singapore markets closed
  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     
  • Nikkei

    39,583.08
    +241.54 (+0.61%)
     
  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     
  • FTSE 100

    8,196.86
    +17.18 (+0.21%)
     
  • Bitcoin USD

    60,888.02
    -1,111.54 (-1.79%)
     
  • CMC Crypto 200

    1,275.10
    -8.73 (-0.68%)
     
  • S&P 500

    5,512.51
    +29.64 (+0.54%)
     
  • Dow

    39,397.67
    +233.61 (+0.60%)
     
  • Nasdaq

    17,959.08
    +100.40 (+0.56%)
     
  • Gold

    2,338.70
    +2.10 (+0.09%)
     
  • Crude Oil

    81.18
    -0.56 (-0.69%)
     
  • 10-Yr Bond

    4.2920
    +0.0040 (+0.09%)
     
  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     
  • Jakarta Composite Index

    7,063.58
    +95.63 (+1.37%)
     
  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

It's Not Just a Bad Day for Chip Stocks. ResMed Is the S&P 500’s Top Decliner.

It's Not Just a Bad Day for Chip Stocks. ResMed Is the S&P 500’s Top Decliner.

ResMed stock was the worst performer in the S&P 500 Monday as Eli Lilly’s weight-loss medicine showed signs of reducing sleep apnea. Lilly said its medication tirzepatide, sold under the brand names Mounjaro and Zepbound, reduced obstructive sleep apnea severity by up to 62.8%. ResMed sells CPAP machines that treat sleep apnea, so this news was not a good sign for investors.